NEWS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Immune Design to Present at Jefferies 2018 London Healthcare Conference
SEATTLE and SOUTH SAN FRANCISCO, Calif. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today that Carlos Paya , M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies 2018 London
View HTML
Toggle Summary Immune Design Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Conference call at 1:30 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today reported financial results and a corporate update for the third quarter
View HTML
Toggle Summary Immune Design Announces Multiple G100 Presentations at the Society for Immunotherapy of Cancer Meeting (SITC) Annual Meeting
New data further support G100’s broad potential in hematological malignancies and solid tumors SEATTLE and SOUTH SAN FRANCISCO, Calif. , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced
View HTML
Toggle Summary Immune Design to Report Third Quarter 2018 Financial Results and Provide Corporate Update
SEATTLE and SOUTH SAN FRANCISCO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report third quarter 2018 financial results after the close of U.S.
View HTML
Toggle Summary Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB305
G100 development to accelerate in follicular lymphoma and beyond CMB305 to be deprioritized to support focus on G100 Cash runway extended into 2021 Conference call at 2:00 pm Pacific today SEATTLE and SOUTH SAN FRANCISCO, Calif. , Oct. 11, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an
View HTML
Toggle Summary Immune Design to Present at Upcoming September Investor Conferences
SEATTLE and SOUTH SAN FRANCISCO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on novel therapies in oncology, today announced that senior management will present at the following upcoming investor conferences: 13 th Annual Wells Fargo Securities
View HTML
Toggle Summary Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update
G100 advancing to late-stage development following FDA feedback Conference call at 1:30 pm Pacific today SEATTLE, WA and SOUTH SAN FRANCISCO, CA , Aug. 01, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq: IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today
View HTML
Toggle Summary Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update
SEATTLE and SOUTH SAN FRANCISCO, Calif. , July 25, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on next-generation therapies in oncology, today announced that it will report second quarter 2018 financial results after the close of U.S.
View HTML
Toggle Summary Immune Design Presents Data on the Mechanism of Action of G100 via TLR4 Expressed in B Cell Malignancies at the Inaugural AACR International Meeting Advances in Malignant Lymphoma
- G100 directly targets and modifies TLR4 expressing malignant B cells making them more visible to the anti-tumor immune response- SEATTLE and SOUTH SAN FRANCISCO, Calif. , June 25, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on novel therapies in
View HTML
Toggle Summary Immune Design to Host June 4 Cancer Immunotherapy Event in Chicago and Present at Jefferies 2018 Global Healthcare Conference in New York
SEATTLE and SOUTH SAN FRANCISCO, Calif. , June 01, 2018 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), an immunotherapy company focused on novel therapies in oncology, today announced that the company will host an event featuring key opinion leaders in the cancer immunotherapy landscape on
View HTML